BTBP: Tiantan Kunming has been approved to conduct clinical trials for "human fibrinogen"
BTBP announced that its subsidiary TianTan Kunming has received approval from the National Medical Products Administration to conduct clinical trials for "human fibrinogen." This product must complete clinical trials, submit a market application, and pass relevant reviews and approval processes before it can be produced and sold on the market
According to the Zhitong Finance APP, BTBP (600161.SH) announced that its subsidiary, China National Pharmaceutical Group Kunming Blood Products Co., Ltd. (referred to as "BTBP Kunming"), has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration, allowing BTBP Kunming to conduct clinical trials for "Human Fibrinogen."
The "Human Fibrinogen" product from BTBP Kunming still needs to complete clinical trials, submit a drug marketing authorization application, pass the review by the Drug Evaluation Center of the National Medical Products Administration, obtain approval from the National Medical Products Administration, and receive a drug registration certificate before it can be produced and marketed
